title: Characterization and anticancer activity of the micelle-forming polymeric anticancer drug adriamycin-conjugated poly(ethylene glycol)-poly(aspartic acid) block copolymer.
abstract: Adriamycin (ADR), an anthracycline anticancer drug, was bound to the poly(aspartic acid) chain of poly(ethylene glycol)-poly(aspartic acid) block copolymer by amide bond formation between an amino group of Adriamycin and the carboxyl groups of the poly(aspartic acid) chain. The polymeric drug thus obtained was observed to form a micelle structure possessing diameter of approximately 50 nm, with a narrow distribution, in phosphate-buffered saline and to show excellent water solubility despite a large amount of ADR introduction. Further, it was able to be stored in lyophilized form without losing its water solubility in the redissolving procedure. Increased stability of the bound Adriamycin molecules in phosphate-buffered saline and elimination of binding affinity for bovine serum albumin due to the micelle formation were further advantages of this polymeric drug. In vivo high anticancer activity of this micelle-forming polymeric drug against P 388 mouse leukemia was obtained with less body weight loss than that seen with free ADR, due to low toxicity as compared with free ADR.
authors.affiliation: Institute of Biomedical Engineering, Tokyo Women's Medical College, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Yokoyama
authors.forename: M
authors.initials: M
authors.lastname: Miyauchi
authors.forename: N
authors.initials: N
authors.lastname: Yamada
authors.forename: T
authors.initials: T
authors.lastname: Okano
authors.forename: Y
authors.initials: Y
authors.lastname: Sakurai
authors.forename: K
authors.initials: K
authors.lastname: Kataoka
authors.forename: S
authors.initials: S
authors.lastname: Inoue
mesh_terms: D000818:Animals; D002470:Cell Survival; D004317:Doxorubicin / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000494:pharmacology / Q000627:therapeutic use; D004337:Drug Carriers; D004355:Drug Stability; D005260:Female; D007202:Indicators and Reagents; D007941:Leukemia P388 / Q000188:drug therapy*; D007942:Leukemia, Experimental / Q000188:drug therapy*; D051379:Mice; D008815:Mice, Inbred Strains; D008823:Micelles; D010455:Peptides / Q000138:chemical synthesis* / Q000494:pharmacology / Q000627:therapeutic use; D011092:Polyethylene Glycols / Q000138:chemical synthesis* / Q000494:pharmacology / Q000627:therapeutic use; D011485:Protein Binding; D012710:Serum Albumin, Bovine / Q000378:metabolism; D014407:Tumor Cells, Cultured / Q000166:cytology / Q000187:drug effects*
chemical_list: D004337:Drug Carriers; D007202:Indicators and Reagents; D008823:Micelles; D010455:Peptides; C063330:doxorubicin-conjugated poly(ethylene glycol)-poly(aspartic acid) block copolymer; D012710:Serum Albumin, Bovine; D011092:Polyethylene Glycols; D004317:Doxorubicin